| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Stanford University |
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00363662 |
Purpose
The overall aim of this project is to prospectively determine whether MRI can improve the conventional neuroradiological evaluation (CT with or without cerebral angiography) of patients with a spontaneous ICH or IVH. The study design will also allow us to identify the added benefit of specific MR sequences and repeat MRI in the chronic stage, thereby allowing us to prospectively determine their value in a consecutive series of patients. This information should have a major impact on the management of these patients by providing data on the diagnostic yield of routine MRI in patients presenting with a wide variety of causes for ICH or IVH. These data will help guide the diagnostic evaluation and the management of brain hemorrhage patients in the future.
| Condition |
|
Cerebral Hemorrhage |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Diagnostic Utility of MRI in Intracerebral Hemorrhage |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:A. Men and non-pregnant women, at least 18 years of age.
B. Patients with an ICH or IVH admitted to Stanford University Medical center within 48 hours of symptom onset.
C. Ability to undergo MRI. Exclusion Criteria:A. Patients with a known (preexisting) source for ICH, for example a known untreated arterio-venous malformation.
B. Patients receiving investigational drug therapies or procedures prior to MRI scanning.
C. Glasgow coma scale (GCS) score < 6 in the absence of sedating medications.
D. Informed consent cannot be obtained either directly from the patient or from a legally authorized representative.
E. Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study
Contacts and Locations| United States, California | |||||
| Stanford University School of Medicine | Recruiting | ||||
| Stanford, California, United States, 94305 | |||||
| Contact: Stephanie M Kemp, BS 650-723-4481 skemp@stanford.edu | |||||
| Contact: Eyngorn, MD (650) 498-7333 ieyngorn@stanford.edu | |||||
| Principal Investigator: Christine Wijman | |||||
| Sub-Investigator: Gregory W Albers | |||||
| Sub-Investigator: Michael E. Moseley | |||||
| Sub-Investigator: Maarten G Lansberg MD, PhD | |||||
| Sub-Investigator: Anna K. Finley Caulfield | |||||
| Sub-Investigator: Neil Schwartz | |||||
| Sub-Investigator: Monisha A Kumar | |||||
| Sub-Investigator: Dr Marion S Buckwalter | |||||
| Sub-Investigator: Dr. chitra venkat | |||||
| Sub-Investigator: James S. Castle | |||||
| Sub-Investigator: Gabor Toth | |||||
| Stanford University |
| Principal Investigator: | Christine Wijman | Stanford University |
More Information
| Study ID Numbers: | 2 R01 NS034866-08A1 |
| First Received: | August 9, 2006 |
| Last Updated: | November 21, 2007 |
| ClinicalTrials.gov Identifier: | NCT00363662 |
| Health Authority: | null:null |
|
|
|
|
